Acute coronary syndromes in Europe: 1-Year costs and outcomes

Current Medical Research and Opinion

Volumn 23, Issue 3, 2007, Pages 495-503

  Taylor, Matthew J ^a   Scuffham, Paul A ^a,b   McCollam, Patrick L ^c   Newby, David E ^d  

^a UNIVERSITY OF YORK   (United Kingdom)

^b GRIFFITH UNIVERSITY   (Australia)

^c ELI LILLY AND COMPANY   (United States)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Acute coronary syndromes; Acute myocardial infarction; Cost of illness; Europe; Unstable angina

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; THIAZIDE DIURETIC AGENT; TICLOPIDINE; VASODILATOR AGENT; WARFARIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG WITHDRAWAL; EUROPE; HEALTH CARE COST; HEART MUSCLE REVASCULARIZATION; HOSPITAL UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; ST SEGMENT ELEVATION; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; ANALYSIS OF VARIANCE; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CAUSE OF DEATH; COMBINED MODALITY THERAPY; CORONARY ARTERY BYPASS; COST OF ILLNESS; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HEALTH CARE COSTS; HEALTH CARE SURVEYS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROBABILITY; QUALITY OF HEALTH CARE; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33947413014     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X167462     Document Type: Article

References (40)

1. Steg PG, Goldberg RJ, Gore JM, et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 2002;90:358-63
2. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Eur Heart J 2001;22:554-72
3. Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. Eur Heart J 2002;23:1190-201
4. OECD Economic Outlook 76 Database. OECD. http://www. oecd.org/document/ 61/0,2340,en_2825_32066506_2483901_ 1_1_1_1,00.html. 2004. 1-3-2005. [Last accessed 7 Nov 2006]
5. InTIME II Investigators. Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Eur Heart J 2001;22:1702-15
6. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes. Variations in practice and outcome. Eur Heart J 2002;23:1177-89
7. Penny WJ. Patient delay in calling for help: the weakest link in the chain of survival? Heart 2001;85:121-2
8. Fox KA, Goodman SG, Anderson FA, et al. From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. Eur Heart J 2003;24:1414-24
9. Fox KA, Cokkinos DV, Deckers J, et al. The ENACT Study: a pan-European survey of acute coronary syndromes. Eur Heart J 2000;21:1440-9
10. Dickson M, Jacobzone S. Pharmaceutical use and expenditure for cardiovascular disease and stroke: a study of 12 OECD countries. OECD Health Working Paper 2003;1
11. Department of Health. Reference Costs 2002. London: Department of Health, 2003
12. Agence Technique de l'Information sur l'Hospitalisation. Echelle nationale des coûts relatifs par GHM. France, 2003
13. Detournay B, Huet X, Fagnani F, Montalescot G. Economic evaluation of enoxaparin sodium versus heparin in unstable angina: a French sub-study of the ESSENCE trial. Pharmacoeconomics 2000;18:83-9
14. G-DRG. Verordnung zum Fallpauschalensystem für Krankenhäuser für das Jahr 2004. Fallpauschalenverordnung 2004 - KFPV 2004. 2003;13
15. G-DRG Group. G-DRG Version 2004: Fallpauschalenkatalog für Hauptabteilungen bzw. Belegabteilungen. In Klauber J, Robra B-P, Schellschmidt H, eds. Krankenhaus-Report 2003. Stuttgart: Schattauer, 2004
16. Consejo General de Colegios Oficiales de Farmaceuticos. Consumer price PVP. Spain, 2003
17. Reverte D, Moreno JJ, Ferreira EM. Hipertension Arterial: Actualizacion de su tratamiento. Informacion Terapeutica del Sistema Nacional de Salud, Spain, 1998;22
18. Blasco A, Gonzalez A, Lobos JM, Silva L. Tratamiento medico de la angina estable: farmacos antianginosos y prevencion secundaria de la cardiopatia isquemica. Informacion Terapeutica del Sistema Nacional de Salud, Spain, 2003;27
19. Danchin N, Macaya C, Tao WY. Economic analysis of the use of contrast media during percutaneous coronary intervention (PCI) in France and Spain. Value in Health 2003;6:659
20. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary 46, 2003. London: Royal Pharmaceutical Society of Great Britain
21. Department of Health. Prescription Cost Analysis 2002. London, 2002
22. Sanitaria Farmaceutica. Giofil 2003, 2003. Italy. Report
23. Assurance Maladie en Ligne. Guide des équivalents thérapeutiques. France, 2003
24. Schwabe U, Paffrath D. Arzneiverordnungs Report 2003. Berlin: Springer, 2003
25. Netten A, Curtis L. Unit costs of health and social care 2002. University of Kent, UK: Personal Social Services Research Unit
26. Stewart S, Murphy N, Walker A. et al. The current cost of angina pectoris to the National Health Service in the UK. Heart 2003;89:848-53
27. Liu JLY, Maniadakis N, Gray A, Rayner M. The economic burden of coronary heart disease in the UK. Heart 2002;88:597-603
28. Brown AID, Garber AM. A concise review of the cost-effectiveness of coronary heart disease prevention. Med Clin North Am 2000;84:279-97
29. Buck D, Godfrey C, Killoran A, Tolley K. Reducing the burden of coronary heart disease: health promotion, its effectiveness and cost. Health Educ Res 1996;11:487-99
30. Francis K. Physical activity in the prevention of cardiovascular disease. Phys Ther 1996;76:456-67
31. Goldman L, Phillips KA, Coxson P, et al. The effect of risk factor reductions between 1981 and 1990 on coronary heart disease incidence, prevalence, mortality and cost. J Am Coll Cardiol 2001;38:1012-17
32. Lightwood J. The economics of smoking and cardiovascular disease. Prog Cardiovasc Dis 2003;46:39-78
33. Salkeld G, Phongsavan P, Oldenburg B, et al. The cost-effectiveness of a cardiovascular risk reduction program in general practice. Health Policy (Amsterdam) 1997;41:105-19
34. World Population Database. United Nations 2002. 15-11-2003. [Last accessed 7 Nov 2006]
35. Moise P, Jacobzone S. OECD study of cross-national differences in the treatment, costs and outcomes of ischaemic heart disease. OECD Health Working Paper 2003;3
36. Marques-Vidal P, Ruidavets JB, Cambou JP, Ferrières J. Incidence, recurrence, and case fatality rates for myocardial infarction in southwestern France, 1985 to 1993. Heart 2000;84:171-5
37. Working Party on Social Policy. Summary of results from ischaemic heart disease study. OECD Workshop 2002;3
38. Maier W, Camici P, Windecker S, et al. The European Registry of Cardiac Catheter Interventions. Eur Heart J 1997;23:1903-7
39. BCIS Audit Returns 2001. British Cardiovascular Intervention Society 2002. 11-11-2003. [Last accessed 7 Nov 2006]
40. Department of Health. Prescription Cost Analysis 2002. London, 2002